- Active, not recruiting
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
Updated: Feb 10
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
Sponsor
Sara V. Latorre
Collaborators
Fondos ARI (Assistencia Recerca Intensiva)
Instituto de Salud Carlos III
Fondo Social La Caixa
ClinicalTrials.gov Identifier: NCT04309981
Official Title: Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA (TNFRSF17) Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor, Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody
First Posted : March 17, 2020
Click here to see details on ClinicalTrials.gov
Biological: Adult differentiated autologous T-cells with anti-BCMA specificity
CARTBCMA-HCB-01
Differentiated Anti-BCMA Autologous CAR T Cells ARI0002h (Code C176769)
ARI 0002h
ARI-0002h
ARI0002h
Autologous Differentiated Anti-BCMA CAR T-cells ARI0002h
CARTBCMA ARI0002h
Differentiated Anti-BCMA Autologous CAR T Cells ARI0002h
J Immunother Cancer; 2021 Dec
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
EHA 2022 Presentation
Type: Presidential Symposium
EHA 2022 - HYBRID - JUNE 9-17 - VIENNA
EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
We report the safety and efficacy results of the CARTBCMA-HCB-01 multicenter clinical trial for patients with relapsed/refractory multiple myeloma (RRMM) (NCT04309981) who received ARI0002h in 5 Spanish centers.
EHA 2022 Presentation
Type: Poster presentation
EHA 2022 - HYBRID - JUNE 9-17 - VIENNA
SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY
Locations
Spain